Sexually Transmitted Disease Testing Market size is expected to cross USD 145 Billion by the end of 2033, growing at a CAGR of 6% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of sexually transmitted disease testing was around USD 95 Billion. An increase in cases of sexually transmitted diseases (STDs) in the younger adult population, followed by unprotected sex and a lower level of awareness about safe sex in younger adults, are expected to increase the transmission of diseases. Hence, it is anticipated to boost the growth of the global market. As per the data reported, every 1 in 4 teens gets infected by STD every year around the globe.
The rise in sexual crimes against women has accelerated the transmission of sexually transmitted infections among women. Rape, sexual molestation, and assault against women are expected to increase sexually transmitted diseases, which are projected to bring lucrative growth opportunities. According to the United Nations, globally, 736 million women, at least once in their lifetime have experienced sexual intimate partner violence, non-partner violence, or both. Furthermore, a higher number of people working as sex workers, insurance covering the treatment of STDs, and increased cases of STDs are propelling the growth of the global STD Testing Market. Moreover, HIV remains a significant public health concern around the world. Therefore, the goal of testing is to identify individuals that are suffering from the STD, so that it cannot be transferred to a healthy person. In the United Kingdom, for instance, the National Chlamydia Screening Program (NCSP) was launched in March 2022. The project's primary objective is to decrease the threat of undiagnosed chlamydia infection.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~6% |
|
Base Year Market Size (2022) |
~ USD 95 Billion |
|
Forecast Year Market Size (2033) |
~ USD 145 Billion |
|
Regional Scope |
|
Disease (Human Immunodeficiency Virus, Herpes Simplex Virus, Human Papillomavirus, Chlamydia, Syphilis, Gonorrhea, Cancroid)
The global sexually transmitted disease testing market is segmented and analyzed for demand and supply by disease into human immunodeficiency virus, herpes simplex virus, human papillomavirus, chlamydia, syphilis, gonorrhea, cancroid, and others. Out of these, the chlamydia segment is expected to garner the highest revenue by the end of 2033. This can be attributed to the higher instances of chlamydia in the younger population owing to unprotected sex and in adults owing to involvement with different partners. Furthermore, there has been surging awareness related to chlamydia treatment, that is further predicted to boost the segment’s growth in the market. According to the World Health Organization, in 2020 there was nearly 129 million instances of chlamydia around the world. The Center for Disease Control and Prevention reported a total of 1,808,703 cases of chlamydia in 2019.
Location (Laboratory, Point of Care)
The STD Testing Market is segmented by location into laboratory and point of care. Out of these, the laboratory segment is expected to garner highest revenue, as laboratories are the most commonly used place for assessing Sexually Transmitted Diseases (STDs) worldwide. The blood screening is performed in laboratories with proper care in order to give correct results, and it is predicted to surge the segment’s growth in the market. Moreover, laboratory tests are precise and trustworthy, their use is widespread, and people place more faith in them, that is further anticipated to surge the segment’s growth in the market. Abbott laboratories provide an in vitro reverse transcription-polymerase chain reaction (RT-PCR) test and an in vitro polymerase chain reaction (PCR) assay for the identification of sexually transmitted diseases induced by Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium, including gonorrhea. Correspondingly, Qiagen Inc. offers a diverse selection of screening test kits, along with STI assessments for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections with significant clinical sensitiveness and specificity, that are utilized to identify a variety of sexually transmitted diseases. More product introductions enable laboratories to configure devices or machinery as needed. For instance, with European Commission authorization, Qiagen Inc. released the NeuMoDxHSV 1/2 Quant Test for the measurement and distinction of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) in May 2022. These factors, as a result, are anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Disease |
|
|
By Location |
|
|
By Device |
|
APAC Market Statistics
The Asia Pacific STD Testing Market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. This can be attributed to the rising crimes related to sexual harassment in the region are increasing the chances of sexually transmitted disease along with the rising population, and the lack of sex education. In 2021, nearly 86 daily rapes and around 50 sexual crimes against women have been reported every hour in India. Moreover, in Thailand, the population of sex workers is around 250,000 to 2 million. Additionally, in 2021, over 20,000 deaths were caused by STDs in China, and nearly 20 thousand people died of AIDS.
North American Market Forecast
On the other hand, the STD Testing Market in North America region is also expected to have a fastest growth owing to the increased incidence of STDs in the region. Moreover, there has been rising number of a substantial of clinical organizations and increased disease consciousness, that is anticipated to drive the market’s growth in the North American region. A survey released in April 2022 by the Centers for Disease Control and Prevention (CDC) titled "Sexually Transmitted Disease Surveillance, 2020" asserted that STDs persist as a major public health issue in the nation. Based on the same source, Chlamydia trachomatis disease was the highest common reportable sexually transmitted infection in the United States in 2020, with 1,579,885 people infected as per the CDC.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?